PDCD1 and melanoma: In line with this, melanomas with acquired resistance to MAPK inhibitors show CD8 T-cell deficiency/exhaustion and loss of antigen presentation functions, which suggests cross-resistance to anti-PD1/Programmed Death-Ligand 1 (PD-L1) immunotherapy (145–147).